The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessAbstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 3,101–3,200 of 3,967
Management of Idiopathic Pulmonary Fibrosis
Cerri, S., Spagnolo, P., Luppi, F., Sgalla, G., & Richeldi, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00004-5 · Cited by 1
Idiopathic Interstitial Pneumonias
Homer, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-39308-9.00016-9 · Cited by 1
Current advances in the treatment of autoimmune-associated interstitial lung diseases
Lee, S., & Lee, J. H. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.4.264 · Cited by 1
Treatment of idiopathic pulmonary fibrosis with an extracellular vesicle isolate product
Bligh, R. (2021) · International Journal of Science and Research Archive · doi:10.30574/ijsra.2021.2.2.0060 · Cited by 1
Update in Diagnosis of Idiopathic Pulmonary Fibrosis and Interstitial Lung Abnormality
Nam, B. D., & Hwang, J. H. (2021) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2021.0072 · Cited by 2
Mortality differences in pulmonary fibrosis among the most populated states in the United States
Jeganathan, N., & Sathananthan, M. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106565 · Cited by 1
Feshchenko, Y. I., Gavrysyuk, V. K., Горовенко, Н. Г., Dziublyk, Y., & Liskina, I. V. (2021) · Ukrainian Pulmonology Journal · doi:10.31215/2306-4927-2021-29-3-5-23 · Cited by 2
Prasse, A. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005615 · Cited by 1
Effect of pirfenidone on wound healing in lung transplant patients
Mortensen, A., Cherrier, L., & Walia, R. (2019) · Multidisciplinary Respiratory Medicine · doi:10.4081/mrm.2018.149 · Cited by 1
New Lung Imaging Findings in Chronic Respiratory Diseases
Ash, S. Y., & Washko, G. R. (2017) · Barcelona Respiratory Network · doi:10.24875/brn.m17000011 · Cited by 1
de Andrade, J. A., Luckhardt, T., Sonavane, S. K., Crowe, D. R., Kulkarni, T., Lara, M. D. P. A., Gulati, S., Il-Kim, Y., Ramachandran, R., & O'Beirne, R. (2023) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v40i1.11460 · Cited by 2
Ozasa, M., Fukuoka, J., & Smith, M. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79547-0.00017-5 · Cited by 1
Caminati, A., Inas, A. W. A. D., Elia, D., Cassandro, R., Mozzanica, F., Pelosi, G., Zompatori, M., & Harari, S. A. (2023) · Minerva Medica · doi:10.23736/s0026-4806.23.08720-7 · Cited by 1
Pirfenidone in fibrotic hypersensitivity pneumonitis: is it ready for prime time?
Assayag, D., & Chaudhuri, N. (2023) · Thorax · doi:10.1136/thorax-2023-220250 · Cited by 1
Brown, S.-A. W., & Braman, S. S. (2023) · Springer eBooks · doi:10.1007/978-3-030-01782-8_55-1 · Cited by 1
Matson, S. M., & Lee, J. S. (2023) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2023.07.002 · Cited by 1
Idiopathic Interstitial Pneumonias
Barış, S. A., Başyiğit, İ., & Nathan, S. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-22483-6_88-1 · Cited by 1
Self-citationAlgorithmic approach in the management of COVID-19 patients with residual pulmonary symptoms
Guri, A., Groner, L. K., Escalon, J. G., & Saleh, A. G. (2023) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_83_23 · Cited by 1
Lee, H. Y., Jung, S. Y., Jang, J. H., Ko, J., Kim, D.-W., Her, M., & Lee, J. H. (2023) · Life · doi:10.3390/life13112118 · Cited by 1
Pirfenidone, Fluorofenidone and New Antifibrotic Drugs: Biochemistry of Direct and Indirect Effects
NISHIZAWA, M., & Nishizawa, K. (2018) · Annals of Biomedical Research · doi:10.61545/abr-1-101 · Cited by 1
Sinha, L., & Karmakar, S. (2023) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-99-4939-7_15 · Cited by 1
Pulmonary fibrosis treatment in children – What have we learnt from studies in adults?
Jia, M. B., & Fitzgerald, D. A. (2023) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2023.12.001 · Cited by 1
Üzer, F., AKANLAR, S., & Çilli, A. (2023) · Tuberkuloz ve Toraks · doi:10.5578/tt.20239603 · Cited by 4
Brown, S.-A. W., & Braman, S. S. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_55 · Cited by 1
DESAFIOS E PERSPECTIVAS NA GESTÃO DA FIBROSE PULMONAR IDIOPÁTICA: RUMO A TERAPIAS MAIS EFICAZES
Silva, A. S., Bomfim, V. V. B. D. S., Brito, I. R. A. X., Bucciaroni, R., Oliveira, P. M. R. E., Bezerra, B. W. W., Costa, L. M. M., & Neto, H. J. R. (2024) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v10i4.13558 · Cited by 1
Gezer, N. S. (2024) · Türk Radyoloji Seminerleri · doi:10.4274/trs.2024.23114 · Cited by 2
Matson, S. M., & Lee, J. S. (2024) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2023.07.005 · Cited by 1
New Therapies in Outpatient Pulmonary Medicine
Granados, L., John, M. M., & Edelman, J. D. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.011 · Cited by 1
Avanços no tratamento da fibrose pulmonar idiopática
Fonseca, L. P. D. S., Martins, M. L. L. S., Sperandio, P. L., et al. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n3-259 · Cited by 1
Approach to the patient with Childhood Interstitial and Diffuse Lung Disease
Fiorino, E. K., & Fishman, M. P. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.27162 · Cited by 1
Kulkarni, T., Newton, C. A., Gupta, S., Samara, K. D., & Bernstein, E. J. (2024) · Pulmonary Therapy · doi:10.1007/s41030-024-00267-x · Cited by 1
Erten, H. Ç. (2024) · Eurasian Journal of Pulmonology · doi:10.14744/ejp.2024.8005 · Cited by 1
Rare diseases: What rheumatologists need to know?
do Nascimento, R. R. N. R., Piotto, D. G. P., Freire, E. A. M., Neves, F. D. S., Sztajnbok, F., Bica, B. E. R. G., Pinheiro, F. A. G., Kozu, K. T., Pereira, I. A., Azevedo, V. F., et al. (2024) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-024-00407-6 · Cited by 2
Factors associated with non-intervention of antifibrotic agents in IPF patients
Asami‐Noyama, M., Hamada, K., Asai, Y., Abé, T., Yonezawa, K., Watanabe, M., Hisamoto, Y., Murakawa, K., Fukatsu, A., Matsuda, K. M., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.09.008 · Cited by 2
Tetikkurt, C. (2024) · doi:10.69860/nobel.9786053359517 · Cited by 1
Lung Fibrosis on CT Imaging: Essentials and Updates
Canivet, P., & Coche, E. (2024) · Journal of the Belgian Society of Radiology · doi:10.5334/jbsr.3775 · Cited by 1
Okamoto, M., Fujimoto, K., Chikasue, T., Yanagihara, T., Tabata, K., Zaizen, Y., Tominaga, M., Sumi, A., Takeoka, H., Matsuo, N., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.12.005 · Cited by 2
Okamoto, M., Yanagihara, T., Fujimoto, K., Chikasue, T., Tabata, K., Zaizen, Y., Tominaga, M., Sumi, A., Nishii, Y., Matsuo, N., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247865 · Cited by 1
Innovation through imitation: IL-33 decoys show promise in pulmonary fibrosis
Kotas, M. E., & Gordon, E. D. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2024.100035 · Cited by 1
Pal, R., Barney, A. M., Sgalla, G., Walsh, S. L. F., Sverzellati, N., Fletcher, S., Cerri, S., Cannesson, M. P., & Richeldi, L. (2025) · Physiological Measurement · doi:10.1088/1361-6579/ada9c0 · Cited by 1
Lee, L., Jan, I., Chou, W.-R., Liu, W., Kuo, Y., Chang, C.-Y., Chang, H.-C., Liu, J.-L., Hsu, C., Lin, C., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031378 · Cited by 2
Gando, Y., Hoshino, M., Ikuta, R., et al. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70046 · Cited by 1
Nishikiori, H., Nakamura, K., Takei, R., et al. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.04.008 · Cited by 1
Perioperative nintedanib for lung resection in patients with idiopathic pulmonary fibrosis
Sumiya, R., Banno, T., Ueno, H., Hirayama, S., & Suzuki, K. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2854 · Cited by 3
Marinescu, D.-C., & Ryerson, C. J. (2025) · CHEST Journal · doi:10.1016/j.chest.2024.12.005 · Cited by 1
Influence of Race and Ethnicity on the Precision Diagnosis and Treatment of ILD
Ferraro, V., & Morisset, J. (2025) · Respiratory medicine · doi:10.1007/978-3-031-87183-2_7 · Cited by 1
A multimorphic variant in ThPOK causes an inborn error of immunity with T cell defects and fibrosis
Vaseghi‐Shanjani, M., Sharma, M., Yousefi, P., Samra, S., Laverty, K. U., Jolma, A., Razavi, R., Yang, A. W. H., Albu, M., Golding, L., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241174 · Cited by 1
Cheng, H., Gao, T., Sun, Y., Huang, F., Gu, X., Shan, C., Luo, S., & Wang, B. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00604.2024 · Cited by 3
Okamoto, M., Yanagihara, T., Zaizen, Y., Fujimoto, K., Chikasue, T., Sumi, A., Tabata, K., Tominaga, M., Matsuo, N., Nouno, T., et al. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.07.014 · Cited by 1
Singh, P., Thampi, G., Gupta, K., Gangte, N., PATTNAIK, B. R., Agrawal, A., & Kukreti, R. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2543473 · Cited by 3
Novel Drug Targets in Diastolic Heart Disease
Er, T., Martinac, B., & Hool, L. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168055 · Cited by 1
“However, the drug has been reported to have deleterious gastrointestinal and skin-related adverse effects [33].”
Kim, S., Kim, Y., Kim, T. S., Kang, J.-H., Yun, I.-Y., Lee, E.-S., Lee, E. J., Kim, R.-K., Yi, J. M., Choi, H. S., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02421-6 · Cited by 4
Biomarkers in interstitial lung disease: moving towards composite indexes and multimarkers?
Ask, K., Hambly, N., & Kolb, M. R. J. (2015) · Current Pulmonology Reports · doi:10.1007/s13665-015-0123-7 · Cited by 2
Atención al final de la vida en los pacientes con fibrosis pulmonar idiopática
Miranda, D. G., Peces, E. M. S., Babarro, A. A., et al. (2014) · Medicina Paliativa · doi:10.1016/j.medipa.2014.07.001 · Cited by 1
Review of the British Thoracic Society Winter Meeting 2013, 4–6 December, London, UK
Chalmers, J. D., Greening, N. J., José, R. J. P., & Janes, S. M. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-205177 · Cited by 2
Sarivalasis, A., Papaefthymiou, O., & Egger, B. (2015) · International Journal of Case Reports and Images · doi:10.5348/ijcri-2015122-cr-10583 · Cited by 1
“Randomized data suggest pirfenidone to slow IPF functional decline [5–9].”
BackgroundPrimer Consenso Mexicano sobre Fibrosis Pulmonar Idiopática
Mejía, M. E., Buendía-Roldán, I., Mateos‐Toledo, H., Estrada, A., Espinoza-Hernández, M., Juárez-Hernández, F., Vargas-Domínguez, C., & Selman, M. (2016) · NCT Neumología y Cirugía de Tórax · doi:10.35366/65161 · Cited by 8
ATS Core Curriculum 2016. Part IV. Adult Pulmonary Medicine Core Curriculum
Michaud, G. C., Channick, C. L., Law, A. C., McCannon, J. B., Antkowiak, M., Garrison, G. W., Sayah, D. M., Huynh, R. H., Brady, A. K., Adamson, R., et al. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201601-060cme · Cited by 1
Imaging of Diffuse Lung Disease
Chung, J. H., & Kanne, J. P. (2016) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000203 · Cited by 1
The evaluation of disease severity/staging for prognosis
O’Connell, O. J., & Egan, J. J. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005315 · Cited by 1
Traitement de la fibrose pulmonaire idiopathique : approche médicamenteuse
Blin, E., & Cottin, V. (2016) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30059-3 · Cited by 1
Drug Discovery in Tissue Fibrosis
Pinto, S., Hoek, M., Huang, Y., Costet, P., Ma, L., & Imbriglio, J. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12432-1 · Cited by 2
Akute Exazerbation der IPF – revidierte Definition und Diagnosekriterien
Markart, P., & Günther, A. (2017) · Pneumo News · doi:10.1007/s15033-017-0601-4 · Cited by 1
Downey, G. P., & Aschner, Y. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1921ed · Cited by 1
Condoluci, C., Inchingolo, R., Mastrobattista, A., Comes, A., Golfi, N., Boccabella, C., & Richeldi, L. (2017) · European Respiratory Society eBooks · doi:10.1183/2312508x.10002017 · Cited by 2
Acute exacerbation of idiopathic pulmonary fibrosis
Avdeev, S. N. (2018) · PULMONOLOGIYA · doi:10.18093/0869-0189-2018-28-4-469-482 · Cited by 3
The Hypoxic Adenosine Response and Inflammation in Lung Disease
Philip, K., & Blackburn, M. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813832-8.00002-9 · Cited by 1
Wang, J., Parys, M. V., Pan, L., Chen, Y., Cheung, D. S., McKnight, J., Milanowski, D. J., Ding, X., & Dean, B. (2019) · Biomedical Chromatography · doi:10.1002/bmc.4482 · Cited by 1
Real-World Comprehensive Disease Management of Patients With Idiopathic Pulmonary Fibrosis
Mason, W. R., McLaughlin, S., Dedopoulos, S., Mahoney, E., Meadows, T., Stauffer, J. L., & LANCASTER, L. H. (2019) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x15666190212155051 · Cited by 1
Self-citation4. Recent Progress in Diagnosis and Treatment of Interstitial Pneumonias
Nishioka, Y. (2018) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.107.505 · Cited by 1
Galindo, J. L., Celis-Preciado, C. A., Pontificia Universidad Javeriana. Bogotá, C., Mejía, M. E., & Unidad de Enfermedades Pulmonares Intersticiales. Instituto Nacional de Enfermedades Respiratorias, I. C. V. C. D. M. (2018) · Investigación Clínica · doi:10.22209/ic.v59n4a07 · Cited by 1
The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
LIMPER, A. H. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201907-1298ed · Cited by 1
Scott, D. A., Loveman, E., Colquitt, J. L., & O’Reilly, K. M. (2019) · Medicina · doi:10.3390/medicina55080443 · Cited by 1
“ASCEND [19], Phase III % predicted at 52 weeks a; Litres at 52 weeks X b X X X Not included X”
BackgroundInfluentialIdiopathic interstitial pneumonias
Averyanov, A., Коган, Е. А., Lesnyak, V., Stepanyan, I. E., & Васильевна, Д. О. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815375-8.00002-9 · Cited by 1
Genetic Determinants of Interstitial Lung Diseases
Mathai, S. K., Schwartz, D. A., & Borie, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812532-8.00015-x · Cited by 1
Hamman–Rich syndrome in a young child
Александровна, М. Т., Mizernitsky, Y. L., Разинькова, Н. С., Владимировна, С. А., & Kostyuchenko, M. V. (2019) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2019-64-4-83-87 · Cited by 1
Patete, C. L., Toonkel, R. L., & Glassberg, M. K. (2019) · Springer eBooks · doi:10.1007/978-3-030-29403-8_7 · Cited by 1
Self-citationGenetics of Idiopathic Pulmonary Fibrosis
Mathai, S. K., & Schwartz, D. A. (2020) · Respiratory medicine · doi:10.1007/978-3-030-31507-8_6 · Cited by 1
Acute Exacerbations in Patients With Idiopathic Pulmonary Fibrosis
Kim, D. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00011-2 · Cited by 1
Carrera, L. G., & Álvarez-Sala, J. L. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2015.06.004 · Cited by 2
Idiopathic Interstitial Pneumonias
Ryu, J. H., Selman, M., Colby, T. V., & King, T. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00063-4 · Cited by 2
Self-citationAboudara, M. C., & Maldonado, F. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2995
Real-World Data on Bleeding Risk and Anticoagulation in Patients with IPF Treated with Antifibrotics
Bendstrup, E. M., & Kalluri, M. (2020) · Drug Safety · doi:10.1007/s40264-020-00991-8 · Cited by 1
Interstitial lung diseases: the role of HRCT in in the era of antifibrotic therapy
Santana, A. N. C., & Soares, F. D. S. N. (2020) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20200457 · Cited by 1
Idiopatic pulmonary fibrosis: A simple approach to a complex problem
Alvarado, A. (2020) · Clinical Research and Trials · doi:10.15761/crt.1000309 · Cited by 1
Antifibrotische Therapie – neue Indikationen bei Non-IPF-interstitiellen Lungenerkrankungen
Markart, P., Drakopanagiotakis, F., & Wygrecka, M. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1239-3728 · Cited by 1
“[3] King TE, Bradford WZ, Castro-Bernardini S et al.”
BackgroundCurrent and future treatment for idiopathic pulmonary fibrosis
Choi, W.-I. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.4.256 · Cited by 1
Treatment of chronic fibrosing interstitial lung diseases
Lee, J. M. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.4.277 · Cited by 1
Idiopathic pulmonary fibrosis complications: what a radiologist should know
Mereu, M., Scutti, M., Veri, D., Conte, S., Patea, R. L., Calandriello, L., Palmucci, S., Valentini, A., Farchione, A., & Larici, A. R. (2021) · Journal of Radiological Review · doi:10.23736/s2723-9284.21.00136-0 · Cited by 1
Questions of ethical regulation of immunobiological therapy of some occupational lung diseases
Shpagina, L. A., Паначева, Л. А., & Золотухина, Е. В. (2021) · Perm Medical Journal · doi:10.17816/pmj383131-140 · Cited by 1
Kirsten, D., de Vries, U., Costabel, U., Koschel, D., Bonella, F., Günther, A., Behr, J., Claussen, M., Schwarz, S., Prasse, A., et al. (2021) · Pneumologie · doi:10.1055/a-1334-2745 · Cited by 1
Fibrosis pulmonar idiopática. Características clínicas de un registro en Panamá. 2017-2020
Noriega, L., Guevara, E., Jiménez, R., Jaramillo, F., Márquez, F., Perea, T., & Evia, E. (2021) · Revista médica de Panamá · doi:10.37980/im.journal.rmdp.20211809 · Cited by 1
Berry, G. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-29683-8_5 · Cited by 1
Vancheri, C. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005715 · Cited by 1
Idiopathic Pulmonary Fibrosis: What Is the Best Treatment?
Wu, X., Kaner, R. J., & Martínez, F. J. (2017) · Barcelona Respiratory Network · doi:10.24875/brn.m17000009 · Cited by 1
Neumonías intersticiales idiopáticas
Velasco, D., Alonso, I. J., Bobillo, J. R., & Oriol, A. J. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.09.011 · Cited by 2
Hypersensitivity pneumonitis: An infrequent cause of chronic lung fibrosis in Africa?
Wong, M. (2022) · African Journal of Thoracic and Critical Care Medicine · doi:10.7196/ajtccm.2022.v28i4.283 · Cited by 1
Ntiamoah, P., Purpura, R., Vehar, S. J., Coley, C., Hasvold, J., Schmidt, L. A., Flaherty, K. R., & Tolle, L. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_34 · Cited by 2
Zarogoulidis, P., Matthaios, D., Huang, H., et al. (2023) · Medicina · doi:10.3390/medicina59040787 · Cited by 1
“Surgical lung biopsy is currently considered the gold standard for a definitive histological diagnosis in over 90% of cases [2,5,6].”
BackgroundCottin, V., & Cordier, J.-F. (2014) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2014.10.725
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.